Evan Clark
Snakebite envenoming remains a significant global health concern, particularly in tropical and subtropical regions where venomous snake species are prevalent. Current treatment relies heavily on antivenom therapy derived from immunized animals; however, this approach presents several challenges, including the risk of adverse immune reactions, limited efficacy against specific toxins, and difficulties in large-scale production. In recent years, the development of single-stranded DNA aptamers targeting snake venom toxins has emerged as a promising alternative therapeutic strategy. Aptamers, short single-stranded oligonucleotides, can be engineered to bind with high specificity and affinity to target molecules, making them an attractive option for neutralizing venom components. The selection of aptamers against snake venom toxins is typically achieved using the systematic evolution of ligands by exponential enrichment (SELEX) process.
PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
